Biotech Startups
9,871 companies tagged Biotech, with their investors and founders.
Octave develops blood-based biomarker tests for neurodegenerative diseases including multiple sclerosis, Parkinson's disease, and Alzheimer's disease. The company's tests enable physicians and patients to measure disease progression and treatment response through blood draws rather than traditional clinical assessments.
3 investors
Oculis is a biopharmaceutical company developing pharmaceutical drug products, with a focus on ophthalmic and eye disease treatments. It conducts formulation, process, and analytical development to advance drug candidates from early research through later development stages.
3 investors
Oculogica develops FDA-cleared concussion assessment devices that use proprietary eye-tracking technology to measure abnormal eye movements caused by traumatic brain injury. Its tools serve clinicians and athletic trainers across settings including sports sidelines, pediatric and urgent care clinics, accident/personal injury clinics, and military care.
3 investors
Mooji Meats develops a proprietary Cross-Fiber Assembly platform that adds meaty whole-cut textures to plant-based and real-meat proteins at scale, with a flagship line of plant-based filet mignons. It sells its Offbeast products direct to home cooks and to restaurants through foodservice channels.
3 investors
Ohalo develops agricultural products designed to improve farmer productivity and livelihoods globally. The company focuses on solving farming challenges through innovation.
3 investors
Olive develops machine learning and signal processing technology with applications across education, mobility, and healthcare sectors. The company combines expertise in ML, signal processing, and biomedical engineering to deliver field-tested solutions.
3 investors
ONASPORT is a wearable device that monitors athletic performance through non-invasive analysis of sweat-based biomarkers including lactate, sodium, dehydration, and electrolyte loss. The system connects via Bluetooth to a cloud-based app for iOS and Android, enabling athletes to track training data and manage team performance.
3 investors
Oncko develops machine learning and experimental platforms to discover optimized multi-drug cancer treatment combinations by screening against resistance mechanisms. The company serves oncology drug developers seeking to identify efficacious combination regimens for cancer indications.
3 investors
OncoPrecision develops precision oncology medicines, including antibody-drug conjugates and bispecific antibodies, for blood cancers and hard-to-treat solid tumors. The company uses patient-derived tumor biology and AI-enhanced discovery to identify therapeutic targets and engineering approaches.
3 investors
One Codex provides microbiome sequencing data analysis and reporting software for academic labs, biotechnology companies, and clinical laboratories. The platform uses advanced algorithms and a curated database to analyze metagenomic samples with a web-based interface accessible to both bench scientists and computational biologists.
3 investors
Oobli develops sweet proteins derived from equatorial fruits and berries, using a fermentation process to produce a sugar alternative that is thousands of times sweeter than sugar. The company creates consumer products made with these fermentation-produced sweet proteins as a healthier form of sweetness.
3 investors
Opo develops bio-based ingredients and cell lines for cosmetic, medical, and cultivated meat applications using synthetic biology and biomanufacturing. The company supplies high-performance biomaterials and multi-species cell banks to biotech and food production customers.
3 investors
Orakl Oncology, a spin-off from Gustave Roussy, builds an AI-and-biology platform that grows patient-derived tumor organoids and enriches them with genomic, transcriptomic, phenotypic, and clinical data to predict drug response and clinical trial outcomes. It offers O-Predict for anticipating clinical endpoints and biomarkers and O-Target for therapeutic target discovery, serving biopharma companies in oncology drug discovery and development.
3 investors
A pharmaceutical company developing therapeutics across oncology, hematology, neuroscience, immunology, and cardiovascular disease with a pipeline of 50 compounds targeting 40+ disease areas.
3 investors
Orbus Therapeutics is a clinical-stage biopharmaceutical company developing eflornithine (DFMO), an oral ODC inhibitor, as a cancer therapy. Its lead candidate targets recurrent grade 3 IDH-mutant astrocytoma and other cancers with ODC overexpression.
3 investors
Orchestra is a platform that unifies scientific, operational, and financial data into a single intelligent environment serving biotech and research teams. It functions as both a system of record and intelligence layer to enable data-driven decision-making and operational alignment.
3 investors
Currax Pharmaceuticals develops and markets a portfolio of therapies for chronic progressive diseases. The company works within the healthcare and pharmaceutical industry to address patient health challenges.
3 investors
OrganoidSciences develops organoid-based regenerative therapeutics and evaluation solutions, operating dedicated GMP manufacturing facilities for cell/organoid drug production. Its lead program ATORM-C is an organoid therapy for inflammatory bowel disease, with clinical development across Korea, the US, and Europe.
3 investors
Ori Biotech develops manufacturing automation platforms for cell and gene therapies, addressing scalability and cost barriers that limit patient access to these treatments.
3 investors
Oricell Therapeutics (εε―ηη©) is a clinical-stage biopharmaceutical company developing cell therapies, including CAR-T products targeting GPRC5D for relapsed/refractory multiple myeloma and GPC3 for advanced liver cancer. Based in Shanghai, it builds proprietary antibody and CAR platforms (OriAb, OriCAR) to create cancer immunotherapies for unmet oncology needs such as liver, gastric, pancreatic, biliary, and ovarian cancers.
3 investors
Orna Therapeutics develops RNA and lipid nanoparticle (LNP) based therapies for treating diseases including oncology and cell therapy applications. The company leverages proprietary drug development expertise in oRNA and LNP technology platforms.
3 investors
OSSIO develops OSSIOfiber, a bio-integrative bone fixation implant material made from natural mineral fibers that provides stability during healing and integrates fully into bone over 18-24 months, avoiding permanent metal hardware. The implants are used in orthopedic surgical procedures such as hammertoe and other bone-healing treatments.
3 investors
Oui Therapeutics develops prescription digital therapeutics aimed at suicide prevention, including what it describes as the first digital therapeutic for suicide, currently in clinical trials. The company works with digital therapy and suicide experts to address suicidal behavior.
3 investors
Ouro Medicines is a biotechnology company developing cell-depleting therapies aimed at resetting the immune system to treat chronic immune-mediated diseases such as autoimmune and autoinflammatory conditions. It is advancing a pipeline of biologics and small molecules across immunology and related therapeutic areas.
3 investors